Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Ianalumab by Novartis for Hidradenitis Suppurativa: Likelihood of Approval
Ianalumab is under clinical development by Novartis and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II...
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's Ianalumab?
Ianalumab is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in Acquired (Autoimmune) Hemolytic Anemia;Idiopathic Thrombocytopenic...